Press Release: Addex Therapeutics to Report 2019 Full Year Audited Results on April 8, 2020

Geneva, Switzerland, April 6, 2020 --

https://www.globenewswire.com/Tracker?data=xrlSf3j-dGO8bbrb6ZMqGdQF26nr5vs-qqdSFZs4Wzk-Lrj3KNRgd3VZf_h8Sges2cPR7XeUH2DfhqFKgfe31qT67dZGXxHty0qLDm1TTHk=

Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage

pharmaceutical company pioneering allosteric modulation-based drug

discovery and development, will discuss its full year 2019 financial

results, provide a business update and review its pipeline during a

teleconference and webcast for investors, analysts and the media on

Wednesday, April 8, 2020 at 16:00 CEST (15:00 BST/10:00 ET).

Title: Addex Full Year 2019 Financial Results

Conference Call

Date: April 8, 2020

Time: 16:00 CEST (15:00 BST/10:00 ET)

Joining the Conference Call:

1: In the 10 minutes prior to the call start time, call the appropriate

participant dial-in number.

Dial-In Numbers:

-- Switzerland +41 44 580 65 22

-- UK +44 20 30 09 24 70

-- U.S.A +1 87 74 23 08 30

-- https://www.addextherapeutics.com/index.php/download_file/force/215/158/

Other Countries

2: Provide the Operator with the Participation Pin Code: 76258295#

Link to live event online:

1: In the 10 minutes prior to the call start time, sign in online by

following this link

https://www.globenewswire.com/Tracker?data=yNO2Ky02qEqMHQXktx076p2FnmyjUggLYv8Z9S-98I0Nhd6OynMIX2Jga4lzxDxBxyRnptzYw96-B0Sn6zr7Q1Wp-D_JCjH_PAihq__fTMNaUCIykH_iMqddPIW4y0mm6a8o6lgs5NwTDc7aiHAhUPJ5pJkXB6SAQNedeCaVi-Ik27jKRIWCxPhHo_ejg_X-lN0yOVN5hvFLJYNR7SGLJ4BmWmpRmdcCYPSR5pSQLJiBHDc1T2eIfMgHwFdzq0FgT6fnN7OcwzyY2WERdX3jHU_p2IEAfYEvOaHpkEytyTrWcMecg3CSwKDlIH7j5rW2b_atuH6LZaDPOFgB4cG3-S8RX4D9sEhtU3Lr3E4E4IY0gViVSEerqIy1VFI6OU0onWGx4Jsjp9SC6q7faVzdHjyi2ar1f6hb55sQAkjUxMORu2nthFc4Uh7dgTRP92pwU-wB7VTLLwCD3QylaVQv6OuoK7knskT3dQ0rTQZpP2slD74i7YeDVSAAuy_92SPv7IyVsFj6Yqfaw0lJr75xlPkKGdg0KGXoyZy3TE1j0fkVwhmcNi3mcp2XfETZ98WW70_MSYvsB-4hQrbh-M4KoVhqbK1cO-iqNkKK3BQAbG_5acdF_KD117PFlK1s0wdi8rBCOJaxjYR-ySj1hJgclKENavLmjGXLQ2njZ5KsOSgHmK4gSrk2DTL9KCyRrleF

Webex Link.

2: Password: Welcome

About Addex Therapeutics

https://www.globenewswire.com/Tracker?data=xrlSf3j-dGO8bbrb6ZMqGfRjY2Z9RL57gtM56-vdr-xJdx-L_DDmqbNm55SdG2wSw-Ms26m2tHQj5Ai11QgxYr3HjKNWfdqwize2XBZW4X0=

Addex Therapeutics is a clinical-stage pharmaceutical company focused on

the development and commercialization of an emerging class of novel

orally available small molecule drugs known as allosteric modulators for

neurological disorders. Allosteric modulators offer several potential

advantages over conventional non-allosteric molecules and may offer an

improved therapeutic approach to conventional "orthosteric" small

molecule or biological drugs. Addex's allosteric modulator drug

discovery platform targets receptors and other proteins that are

recognized as essential for therapeutic intervention. Addex's lead drug

candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is

scheduled to enter a pivotal registration clinical trial for Parkinson's

disease levodopa induced dyskinesia (PD-LID). In parallel,

dipraglurant's therapeutic use in dystonia is being investigated in

preclinical models. Addex's second clinical program, ADX71149 (mGlu2

positive allosteric modulator or PAM) is being developed in

collaboration with Janssen Pharmaceuticals, Inc for the treatment of

epilepsy. In addition, Addex's GABA(B) PAM program has been licensed to

Indivior PLC for the treatment of addiction. Preclinical programs

include GABA(B) PAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for mild

neurocognitive disorders, mGlu4 PAM for Parkinson's disease and mGlu3

PAM for neurodegenerative disorders.

Press Contacts:

Tim Dyer Mike Sinclair

Chief Executive Officer Partner, Halsin Partners

Telephone: +41 22 884 15 55 +44 (0)20 7318 2955

Email: mailto:PR@addextherapeutics.com PR@addextherapeutics.com mailto:msinclair@halsin.com msinclair@halsin.com

---------------------------------------------------------------- -------------------------------------------------

Forward Looking Statements

Certain statements made in this announcement are forward-looking

statements including with respect to the creation of a trading market

for ADSs representing the Company's shares in the United States. These

forward-looking statements are not historical facts but rather are based

on the Company's current expectations, estimates, and projections about

its industry; its beliefs; and assumptions. Words such as 'anticipates,'

'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and

similar expressions are intended to identify forward-looking statements.

These statements are not guarantees of future performance and are

subject to known and unknown risks, uncertainties, and other factors,

some of which are beyond the Company's control, are difficult to predict,

and could cause actual results to differ materially from those expressed

or forecasted in the forward-looking statements. The Company cautions

securityholders and prospective securityholders not to place undue

reliance on these forward-looking statements, which reflect the view of

the Company only as of the date of this announcement. The

forward-looking statements made in this announcement relate only to

events as of the date on which the statements are made. The Company will

not undertake any obligation to release publicly any revisions or

updates to these forward-looking statements to reflect events,

circumstances, or unanticipated events occurring after the date of this

announcement except as required by law or by any appropriate regulatory

authority.

(END) Dow Jones Newswires

April 06, 2020 01:00 ET (05:00 GMT)